Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

Medicine & Life Sciences

• Human Influenza 100%
• Random Allocation 28%
• Critical Care 25%
• Therapeutics 17%
• Adult Respiratory Distress Syndrome 15%
• Oxygen 15%
• Early Warning Score 11%
• National Institute of Allergy and Infectious Diseases (U.S.) 11%
• Infections 10%
• Transfusion Reaction 9%
• Hemagglutination 8%
• National Institutes of Health (U.S.) 7%
• Orthomyxoviridae 7%
• Psychological Power 6%
• Intention 6%
• Child 6%
• Antiviral Agents 6%
• Anemia 6%
• Intensive Care Units 6%
• Hypersensitivity 5%
• Psychological Inhibition 5%
• Cause of Death 5%
• Placebos 4%
• Pediatrics 4%
• Polymerase Chain Reaction 4%
• Morbidity 4%
• Antibodies 4%
• Mortality 3%
• Population 2%